诚信认证:
工商注册信息已核实！
扫一扫即可访问手机版展台
Fully automated glycoform profiling and sequence validation of the NIST reference antibody
| 领域： | 蛋白/抗体/蛋白质组,生物制药/仿制药 | ||
| 样品： | -- | 项目： | -- |
| 参考： | -- | ||
| 方案文件名 | 下载 |
|---|---|
Fully automated glycoform profiling and sequence validation of the NIST reference antibody |
下载此篇方案 |
BioPharma Compass 2.0 and the maXis II were used for the automated assessment of the NIST antibody using three complementary approaches, intact, subunit domain and bottom-up. This combination provided fast, accurate and in-depth information for antibody analysis using a single software platform. BPC 2.0 was developed for maximum ease-of-use whilst retaining the experimental flexibility required by today’s biopharmaceutical analytical laboratory. The software also supports 21 CFR Part 11 compliant work.
The particular advantages of the described approaches are:
Intact mass: Fast screening for expected glycoforms including low abundant species such as the aglycan and early detection of antibody processing artefacts.
Subunit domain: Accurate mass analysis of antibody subunits on the sub ppm level, glycoform quantitation and further localization of sequence deviations on the Fd, Fc/2 or LC domains (2).
Bottom up: Near 100% sequence and fragment coverage for sequence validation from a single experiment.
